microRNA Companies Strategic Expansion Initiatives

Who are the Leading Companies in the microRNA Market?

• Thermo Fisher Scientific, Inc.
• DiamiR Biosciences
• New England Biolabs
• NanoString Technologies, Inc.
• Sanofi
• miRecule
• Alnylam
• BioGenex
• Merck KGaA
• LGC Limited
• Takara Bio, Inc.
• Horizon Discovery Group plc.
• QIAGEN
• GeneCopoeia, Inc.

Market Growth

The global microRNA market was estimated at US$ 1.61 billion in 2023 and is projected to grow to US$ 6.11 billion by 2034, rising at a compound annual growth rate (CAGR) of 12.89% from 2024 to 2034. The increasing prevalence of chronic conditions is driving the market’s growth.

Top Companies’ Info

• Bio-Techne Corporation is an American life sciences company that develops, manufactures, and sells reagents, instruments, and services. The company offers miRNAscope Assay Red for detecting smRNA. The fourth-quarter 2024 revenue was $306.1 million, and the full-year 2024 revenue was $1.2 billion, an organic increase of 1%.
• Takara Bio, Inc. is a biotechnology company that provides a wide range of life science reagents. The company offers microRNA first-strand synthesis and miRNA quantitation kits. The FY2025 revenue was 45,039 million yen, compared to 43,505 million yen in 2024.

The Biotechnology & Pharmaceutical Companies Segment Dominated

By end-use, the biotechnology & pharmaceutical companies segment dominated the microRNA market in 2023. The main function of microRNA is in therapeutics and various sequencing-associated activities. Both biotechnology and pharmaceutical companies are highly invested in the development of new therapeutics and understanding the function of genes. As the population grows, unhealthy lifestyles and environmental conditions contribute to chronic conditions, pharma, and biotech companies are conducting clinical trials and research studies. Companies are heavily investing and collaborating with other companies and government institutions to come up with better solutions.

For instance,

• In March 2023, The University of Leipzig in Germany and the RNA delivery and therapeutics business SiSaf Ltd. will work together to create tailored micro-interfering RNAs (miRNA) for the treatment of cancer, with a primary focus on pancreatic cancer. In the lab of Achim Aigner, SiSaf will create formulations of miRNA Bio-Courier that will be tested in pancreatic cancer models. As per the agreement, SiSaf is the only party that has the ability to purchase a worldwide license for a patent held by the institution.

Regional Companies Insights

Asia Pacific

• In 2022, MiRXES, a Singaporean company, announced that it would collaborate with the National Heart Centre and National University Heart Centres in Singapore to manage pulmonary hypertension. Thanks to the collaboration, the first multi-center study employing early detection microRNA biomarkers in Southeast Asia has begun. The institute wants to use microRNA biomarkers to identify pulmonary hypertension at an early stage.

Recent Developments in the microRNA Market

• In July 2024, adult mice with a particular kind of hereditary hearing loss have had their hearing restored by researchers using gene editing. They demonstrated that the animal's ability to hear was restored by blocking a defective copy of a gene known as a microRNA (miRNA). The method used by a National Institutes of Health (NIH))-supported research team, published in Science Translational Medicine, may potentially result in hereditary hearing loss remedies for humans.
• In February 2024, the FDA in the United States gave the go-ahead for ARTHEx Biotech S.L. to begin the Phase I-IIa ArthemiRTM study of ATX-01 for the treatment of Myotonic Dystrophy Type 1 (DM1). ARTHEx Biotech S.L. is a clinical-stage biotechnology company focused on developing novel medicines through the modulation of microRNAs.
• In September 2023, Researchers at Purdue University created a novel cancer treatment that targets tumors by deceiving cancer cells into ingesting a little piece of microRNA that normally prevents cell proliferation. According to a paper published in Oncogene on Monday, September 4, during a 21-day trial, tumors treated with the novel therapy did not grow in size, but tumors that were left untreated tripled in size during the same timeframe.

Partner with our experts to explore the microRNA Market at sales@towardshealthcare.com